{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Implementation of a Procainamide-Based Cardioversion Strategy for the Management of Recent Onset Atrial Fibrillation

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Recognize the evidence that supports the need for this study of the safety and efficacy of intravenous procainamide for pharmacological cardioversion.
  2. Choose the results of this study that can help lend insight for clinicians establishing and following protocols for the use of this therapy.

Learning Outcomes

Health care providers will demonstrate knowledge of a retrospective chart review assessing the safety and efficacy of intravenous procainamide for pharmacological cardioversion in patients presenting to the emergency department (ED) with atrial fibrillation of less than 48 hours' duration by achieving a minimum score of 70% on the outcomes-based posttest.
Price: $21.95


  • ANCC 2.0 CH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH
  • GA - BON 2.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Test Code: AENJ0721A
Published: Jul/Sep 2021
Expires: 9/6/2024
Required Passing Score: 7/10 (70%)
Authors: Andrew J. Matuskowitz, MD; Kyle A. Weant, PharmD, BCPS, BCCCP, FCCP; Haili Gregory, PharmD, BCPS; Michael E. Field, MD; Chara Calhoun, PharmD, BCPS; Brent J. Bushkar, MD; Gregory A. Hall, MD; Jeffrey Caporossi, MD